Marksans Pharma Limited — Roxithromycin Exporter Profile
Indian Pharmaceutical Exporter · #3 for Roxithromycin · $598.0K export value · DGFT Verified
Marksans Pharma Limited is the #3 Indian exporter of Roxithromycin with $598.0K in export value and 15 verified shipments. Marksans Pharma Limited holds a 14.3% market share in Roxithromycin exports across 2 countries. The company exports 22 pharmaceutical products worth $125.0M across 11 therapeutic categories.
Marksans Pharma Limited — Roxithromycin Export Profile: Buyers & Destinations
Where Does Marksans Pharma Limited Export Roxithromycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NEW ZEALAND | $347.3K | 10 | 68.5% |
| CAMBODIA | $160.0K | 5 | 31.5% |
Marksans Pharma Limited exports Roxithromycin to 2 countries. The largest destination is NEW ZEALAND accounting for 68.5% of Marksans Pharma Limited's Roxithromycin shipments. These destinations reflect Marksans Pharma Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Roxithromycin from Marksans Pharma Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TEVA PHARMA (NEW ZEALAND) LIMITED | NEW ZEALAND | $177.1K | 5 |
| TEVA PHARMA NEW ZEALAND LIMITED | NEW ZEALAND | $170.2K | 5 |
| ISKP PHARMA CO., LTD | CAMBODIA | $132.1K | 4 |
| ISKP PHARMA CO LTD | CAMBODIA | $27.8K | 1 |
Marksans Pharma Limited supplies Roxithromycin to 4 buyers globally. The largest buyer is TEVA PHARMA (NEW ZEALAND) LIMITED (NEW ZEALAND), followed by TEVA PHARMA NEW ZEALAND LIMITED (NEW ZEALAND) and ISKP PHARMA CO., LTD (CAMBODIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Roxithromycin Export Value and How Much Does Marksans Pharma Limited Contribute?
India exported $2.9M worth of Roxithromycin through 427 shipments from 78 suppliers to 30 countries, serving 125 buyers globally. Marksans Pharma Limited contributes $598.0K to this total, accounting for 14.3% of India's Roxithromycin exports. Marksans Pharma Limited ships Roxithromycin to 2 countries through 4 buyers.
What Is the Average Shipment Value for Marksans Pharma Limited's Roxithromycin Exports?
Marksans Pharma Limited's average Roxithromycin shipment value is $39.9K per consignment, based on 15 shipments totaling $598.0K. The largest destination is NEW ZEALAND (68.5% of Marksans Pharma Limited's Roxithromycin exports).
How Does Marksans Pharma Limited Compare to Other Indian Roxithromycin Exporters?
Marksans Pharma Limited ranks #3 among 78 Indian Roxithromycin exporters with a 14.3% market share. The top 3 exporters are STRIDES PHARMA SCIENCE LIMITED ($758.8K), BRAWN LABORATORIES LIMITED ($700.0K), MARKSANS PHARMA LIMITED ($598.0K). Marksans Pharma Limited processed 15 shipments to 2 destination countries.
What Roxithromycin Formulations Does Marksans Pharma Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA.PRODUCTS.-ROXITHROMYCIN TABLETS 1 | $104.7K | 3 |
| PHARMACEUTICAL PRODUCTS - ROXITHROMYCIN300 MG TABLETS Batch No: 150507,150488,150506 | $50.0K | 1 |
| ROXITHROMYCIN 150 MG TABLETS 12960 PACK | $45.3K | 1 |
| ROXITHROMYCIN 150 MG TABLETS (12030 PACK | $42.1K | 1 |
| ROXITHROMYCIN 300 MG TABLETS 5210 PACKX | $35.9K | 1 |
| PHARMA PRODUCTS-ROXITHROMYCIN 150 MG TABLETS BATCH NO: 131481 | $34.7K | 1 |
| ROXITHROMYCIN 300 MG TABLETS BATCH NO: 131482 | $34.3K | 1 |
| PHARMA PRODUCTS-ROXITHROMYCIN 300 MG TAB | $32.5K | 1 |
| ROXITHROMYCIN 300 MG TABLETS (4680 PACKX | $32.3K | 1 |
| PHARMA PRODUCTS ROXITHROMYCIN TABLETS 150MG ROXIGIN 150 10X10 | $27.8K | 1 |
Marksans Pharma Limited exports 13 distinct Roxithromycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA.PRODUCTS.-ROXITHROMYCIN TABLETS 1 with 3 shipments worth $104.7K.
How Does Marksans Pharma Limited Compare to Nearest Roxithromycin Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | STRIDES PHARMA SCIENCE LIMITED | $758.8K | 54 | 1 | $14.1K |
| 1 | BRAWN LABORATORIES LIMITED | $700.0K | 14 | 4 | $50.0K |
| 3 | MARKSANS PHARMA LIMITED ★ | $598.0K | 15 | 2 | $39.9K |
| 4 | TORRENT PHARMACEUTICALS LTD | $191.6K | 14 | 2 | $13.7K |
| 5 | GLOBAL PHARMA HEALTHCARE PRIVATE LIMITED | $135.0K | 12 | 3 | $11.3K |
Marksans Pharma Limited ranks #3 among 78 Indian Roxithromycin exporters. Average shipment value of $39.9K compared to the market average of $36.7K. The closest competitors by value are STRIDES PHARMA SCIENCE LIMITED and BRAWN LABORATORIES LIMITED.
Which Indian Ports Ship Roxithromycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 64 | 15.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 40 | 9.4% |
| SAHAR AIR | 35 | 8.2% |
| Bombay Air | 29 | 6.8% |
| NHAVA SHEVA SEA (INNSA1) | 25 | 5.9% |
| DELHI AIR | 24 | 5.6% |
| TUGLAKABAD ICD | 14 | 3.3% |
| BANGALORE ICD | 14 | 3.3% |
What Other Advanced Antibiotics Products Does Marksans Pharma Limited Export?
Marksans Pharma Limited also exports these advanced antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Marksans Pharma Limited's Roxithromycin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Marksans Pharma. The ongoing Israel-Iran tensions have led to increased security risks in the Red Sea, a crucial maritime route for trade between Asia and Europe. Major shipping lines have introduced an 'Emergency Risk Surcharge' ranging from $250 to $500 per TEU for cargo transiting the Bab-el-Mandeb Strait, effective February 2025. This surcharge elevates shipping costs, potentially impacting the competitiveness of Indian pharmaceutical exports to European and US East Coast markets. (sgeexport.com)
Conversely, the India–European Union Free Trade Agreement (FTA), concluded in January 2026, offers a silver lining. The FTA eliminates tariffs on Indian pharmaceuticals, APIs, vaccines, and medical devices, providing immediate cost relief and enhancing market access for Indian exporters. This development positions Marksans Pharma favorably to increase its footprint in the European market, leveraging its existing regulatory approvals and manufacturing capabilities. (en.wikipedia.org)
Marksans Pharma Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for pharmaceutical exporters. Marksans Pharma has demonstrated a strong commitment to regulatory compliance. In November 2025, the company's Goa facility underwent a current Good Manufacturing Practice (cGMP) inspection by the US FDA, concluding with zero Form 483 observations. This outcome reflects Marksans' dedication to adhering to international quality standards and regulatory requirements. (capitalmarket.com)
Furthermore, the company's subsidiaries have achieved significant regulatory milestones. Time-Cap Laboratories Inc., Marksans' US subsidiary, received an Establishment Inspection Report (EIR) from the US FDA for its New York-based facility in June 2025, following an inspection that resulted in only one observation with no data integrity issues. Such achievements bolster Marksans' reputation as a reliable and compliant pharmaceutical manufacturer. (business-standard.com)
About Marksans Pharma Limited
Marksans Pharma Limited exports 22 products worth $125.0M. Beyond Roxithromycin, top products include Ibuprofen, Amino, Gabapentin, Acetaminophen, Loratadine. View the complete Marksans Pharma Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Roxithromycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Roxithromycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Marksans Pharma Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 15 individual customs records matching Marksans Pharma Limited exporting Roxithromycin, covering 13 formulations to 2 countries via 4 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 30+ countries, 125+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Roxithromycin Export Data from Marksans Pharma Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Marksans Pharma Limited's Roxithromycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Marksans Pharma Limited
Full Company Profile →
22 products · $125.0M total trade · 11 categories
Roxithromycin Stats
Company Overview
Top Products by Marksans Pharma Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Marksans Pharma Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Roxithromycin. For current shipment-level data, contact TransData Nexus.